Last reviewed · How we verify

DTaP-IPV vaccine and Hib vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

DTaP-IPV vaccine and Hib vaccine is a vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children. Also known as: DD 687; DF 098.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameDTaP-IPV vaccine and Hib vaccine
Also known asDD 687; DF 098
SponsorSanofi Pasteur, a Sanofi Company
Drug classvaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTaP-IPV/Hib is a pentavalent vaccine containing inactivated toxoids (diphtheria and tetanus), acellular pertussis antigens, inactivated poliovirus, and Haemophilus influenzae type b conjugate. It works by presenting these antigens to the immune system, triggering both humoral (antibody) and cell-mediated immune responses that provide protection against these five infectious diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV vaccine and Hib vaccine

What is DTaP-IPV vaccine and Hib vaccine?

DTaP-IPV vaccine and Hib vaccine is a vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

How does DTaP-IPV vaccine and Hib vaccine work?

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

What is DTaP-IPV vaccine and Hib vaccine used for?

DTaP-IPV vaccine and Hib vaccine is indicated for Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

Who makes DTaP-IPV vaccine and Hib vaccine?

DTaP-IPV vaccine and Hib vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is DTaP-IPV vaccine and Hib vaccine also known as anything else?

DTaP-IPV vaccine and Hib vaccine is also known as DD 687; DF 098.

What drug class is DTaP-IPV vaccine and Hib vaccine in?

DTaP-IPV vaccine and Hib vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is DTaP-IPV vaccine and Hib vaccine in?

DTaP-IPV vaccine and Hib vaccine is in Phase 3.

What are the side effects of DTaP-IPV vaccine and Hib vaccine?

Common side effects of DTaP-IPV vaccine and Hib vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability, Drowsiness, Loss of appetite.

Related